Skip to Content

Tivozanib FDA Approval Status

FDA Approved: No
Generic name: tivozanib
Company: AVEO Oncology
Treatment for: Renal Cell Carcinoma

Tivozanib is an investigational tyrosine kinase inhibitor in development for the treatment of advanced renal cell carcinoma.

Development Timeline for tivozanib

DateArticle
Mar 31, 2020AVEO Oncology Announces Submission of New Drug Application to U.S. FDA for Tivozanib in Patients with Relapsed or Refractory Renal Cell Carcinoma
Nov  4, 2019AVEO Oncology Announces Regulatory Update For Tivozanib In Renal Cell Carcinoma
Sep 10, 2019AVEO Oncology Announces Updated Overall Survival Hazard Ratio Of 0.99 In Phase 3 TIVO-3 Trial Of Tivozanib In Renal Cell Carcinoma
Feb 15, 2014AVEO and Astellas to End Worldwide Collaboration & License Agreement for Tivozanib
Dec 16, 2013AVEO Provides Update on Interim Analysis from Tivozanib Trial in Colorectal Cancer
Jun 10, 2013AVEO Announces Complete Response Letter Received for Tivozanib New Drug Application in Renal Cell Carcinoma
May  2, 2013AVEO and Astellas Report FDA Oncologic Drug Advisory Committee Votes Tivozanib Application Did Not Demonstrate Favorable Benefit-to-Risk Evaluation in Treatment of Advanced Renal Cell Carcinoma
Feb 27, 2013AVEO and Astellas Announce FDA Advisory Committee To Review Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
Nov 28, 2012AVEO and Astellas Announce FDA Acceptance of NDA Filing for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma
Sep 28, 2012AVEO and Astellas Announce Submission of New Drug Application for Tivozanib for the Treatment of Advanced Renal Cell Carcinoma

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.